Lenacapavir, the world's first twice-yearly HIV prevention shot, gets US FDA nod-offering a discreet, long-acting solution ...

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...

FDA approval paves the way for the jab to roll out across the world. But with funding being slashed, will it get to the ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...

Learn more about lenacapavir, the most effective HIV treatment and prevention drug, and how its cost could cause a setback.

FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...

The United States Food and Drug Administration (FDA) has approved a twice-a-year drug to be used to prevent HIV.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...